Emerging Nanoparticle Platforms for Precision Drug Delivery: Therapeutic Potential and Safety Challenges

Emerging Nanoparticle Platforms for Precision Drug Delivery: Therapeutic Potential and Safety Challenges

Gaurav. U., Vyshnavi. G., Soumya Ranjan Das., Tajuddin Shaik

Mallareddy College of Pharmacy, India

DOI: https://doi.org/10.51244/IJRSI.2025.120700141

Received: 19 July 2025; Accepted: 21 July 2025; Published: 09 August 2025

ABSTRACT

The advancement of nanotechnology has transformed the landscape of drug delivery systems, providing promising answers to the limits of traditional medicinal techniques. Nanoparticles, with their unique physicochemical qualities such as large surface area, variable size, and varied surface modification capabilities, are effective carriers for targeted and controlled drug delivery. This review covers a wide range of nanoparticle systems used in drug administration, including polymeric, magnetic, protein-based, and mesoporous silica nanoparticles. Each class of nanoparticle is examined in terms of its structural properties, drug loading and release mechanisms, and therapeutic potential. Therapeutic nanoparticles are particularly important in oncology, where focused delivery improves efficacy while reducing systemic toxicity. The utilisation of magnetic nanoparticles for externally guided drug delivery, as well as the development of smart nanoparticles that respond to specific physiological stimuli, are investigated. Furthermore, the study discusses the clinical and experimental applications of these nano-systems, as well as the issues associated with toxicity, scalability, and regulatory compliance. This article intends to provide insight into the potential of nanoparticle-based drug delivery systems to transform the future of precision medicine by combining recent advances and present trends.

Keywords: Nanoparticles, Drug Delivery Systems, Targeted Therapy, Polymeric Nanoparticles, Magnetic Nanoparticles, Smart Nanocarriers, Protein-Based Nanoparticles, Mesoporous Silica Nanoparticles, Cancer Drug Delivery, Nanomedicine.

INTRODUCTION

Drug delivery systems (DDSs) have evolved significantly to address the limitations of traditional approaches. Traditionally, medications were administered via routes such as oral, nasal, inhalational, and parenteral. However, conventional drug delivery systems (CDDSs) frequently suffer from poor absorption, quick clearance, and non-specific distribution, resulting in decreased therapeutic efficacy and increased toxicity. Many medications are supplied as prodrugs, which require metabolic activation, and their effectiveness is heavily dependent on the route of delivery.

To solve these issues, controlled-release systems were created, using hydrogels, osmotic pumps, degradable matrices, and reservoir systems. Despite these developments, several systems still demonstrated poor solubility, low tissue selectivity, and high drug agglomeration, resulting in limited clinical success. [1,2]

Nanotechnology has emerged as a viable way to address these difficulties. First introduced by Richard Feynman in 1959, nanotechnology is the manipulation of materials at the nanoscale (1-100 nm) and has found applications across various scientific areas, including drug delivery. Nanoparticles have distinct physicochemical features, including increased surface area, improved solubility, and focused interaction with biological systems. [3]

Figure 1. Illustration of how traditional medications were administered without the use of nanocarriers and harm was done to healthy organs or cells. In contrast, modern procedures use nanomedicines to transport medications to specific parts of the body.[1]

Since the 1970s, the use of nanoparticles in medicine—known as nanomedicine—has increased significantly. In 2015, thousands of research articles had been published on this topic. Nanocarriers such liposomes, dendrimers, carbon nanotubes, polymer-based nanoparticles, and metallic nanoparticles allow for regulated release, enhanced pharmacokinetics, and selective targeting of sick tissues. Onivyde®, an FDA-approved nanomedicine for cancer therapy, highlights the clinical usefulness of these systems.[4]

Recent advancements include smart nanoparticles that respond to environmental signals and protein-based nanoparticles produced from ferritin, albumin, and gelatin, providing biocompatible and efficient drug delivery platforms. These developments in nanomedicine aim to enhance drug selectivity, reduce toxicity, and improve therapeutic outcomes.

This study examines the types, methods, applications, toxicological concerns, and future possibilities of nanoparticles used in medication delivery, with a focus on cancer, polymeric, magnetic, protein-based, and smart nanocarriers.[5]

General Overview

Nanocarriers are manufactured structures that typically range from 1 to 100 nanometers in at least one dimension, while the term “nano” can also refer to particles that are several hundred nanometers in size. These carriers are intended to improve the transport of bioactive substances by increasing cellular absorption, targeting, and regulated release of therapeutic drugs. Liposomes, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), polymeric nanoparticles (PNPs), and dendrimers are some of the most common types of nanocarriers, each with their own set of advantages for drug administration. [6]

Figure 2. Nanoparticle drug delivery systems with relation to other scales [6]

Liposomes are spherical vesicles made of phospholipids and cholesterol that typically measure between 80 and 300 nanometers. They can encapsulate both hydrophilic and hydrophobic medicines, which improves solubility and pharmacokinetics. Liposomal formulations are commonly utilized to deliver anticancer, antibacterial, and anti-inflammatory medicines. Their surfaces can be changed with ligands or antibodies to achieve targeted distribution, and cationic liposomes have proven particularly useful for gene delivery. [6,7]

Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are another type of nanocarrier. SLNs are composed of solid lipids stabilized by surfactants, which provide good stability and protection for encapsulated medicines against degradation. NLCs, which blend solid and liquid lipids, provide greater drug payload while preventing drug evacuation during storage. Both SLNs and NLCs are versatile, allowing for cutaneous, oral, and parenteral administration. [7]

Polymeric nanoparticles are made from synthetic or natural polymers and typically measure 10 to 100 nanometers in size. They can be biodegradable, such as those derived from polylactic acid (PLA) or polyglycolic acid (PGA), or non-biodegradable. Drugs can be immobilized on the surface or contained within the polymer matrix, with release determined by desorption, diffusion, or erosion. Polymeric nanoparticles are known for their biocompatibility, stability, and the ability to tailor their surfaces to reduce immune responses and improve targeting. [9]

Dendrimers are extremely branching, tree-like polymers made composed of a specified core, dendrons, and several surface functional groups. These novel structures can encapsulate pharmaceuticals within their inner voids or attach them to their surfaces, allowing for polyvalent interactions and highly targeted administration. Surface changes, such as the inclusion of folic acid, antibodies, or polyethylene glycol (PEG), can improve selectivity while reducing toxicity. Poly(amido amide) (PAMAM) dendrimers are among the most widely employed in biomedical research and pharmaceutical delivery. [8,9]

Drugs are loaded onto or into nanocarriers via a variety of ways, including adsorption, covalent attachment, and encapsulation. Covalent attachment, in particular, enables precise control over both the amount of drug loaded and the release profile. Targeting techniques can be either active, in which ligands on the carrier surface selectively recognize and bind to target cells, or passive, in which the carrier takes advantage of the increased permeability and retention (EPR) effect observed in tumour vasculature. Controlled drug release from nanocarriers can be initiated by environmental changes such as pH, temperature, or the presence of certain enzymes, as well as external stimuli such as electromagnetic fields.

Nanocarriers must be biocompatible and safe. Their safety profile is determined by various aspects, including size, shape, surface chemistry, dosage, and method of administration. Smaller nanoparticles have a bigger surface area, which makes them more reactive and potentially hazardous. In general, particles between 10 and 100 nanometers have the best pharmacokinetic properties. Each novel formulation must go through extensive toxicological testing, as interactions with the immune system and clearance rates might differ greatly depending on the carrier’s qualities. [6]

Liposomal formulations are already utilized in clinical practice to deliver a variety of medications, including anticancer agents and antibiotics. Solid lipid nanoparticles and NLCs are used in cutaneous, oral, and parenteral drug administration, whereas polymeric nanoparticles are being developed for targeted cancer therapy, HIV medicines, and neurological disease treatments. Dendrimers are being investigated for their potential use in targeted chemotherapy and imaging agents. Overall, nanocarriers such as liposomes, solid lipid nanoparticles, polymeric nanoparticles, and dendrimers are sophisticated drug delivery platforms that provide better targeting, controlled release, and increased therapeutic efficacy. Their design and application are constantly evolving, spurred by the continued demand for safer and more effective medical treatments. [6,8,9]

Types of Nanoparticles

Mesoporous silica Nanoparticles

Mesoporous Silica Materials (MSMs) were initially presented in the 1990s and are distinguished by their organized pore architectures, large surface area, and high pore volume. These properties make MSMs ideal for applications that require the adsorption and release of molecules, such as medication delivery. Their silanol-rich surface facilitates functionalization, and their chemical resemblance to bioactive glasses has led to their usage in bone tissue engineering. The outstanding textural and chemical features of bulk MSMs prompted the development of mesoporous silica nanoparticles (MSNs), which have subsequently been extensively studied for biological applications such as cancer therapy, infectious disease treatment, and imaging agents. Advances in nanotechnology have enabled the development of multifunctional MSNs, paving the possibility for more personalized and targeted medicinal therapies.

MSNs are commonly synthesized via the sol-gel technique, in which silica precursors condense around surfactant templates before being removed to form a porous structure. The resultant nanoparticles, which are typically between 50 and 300 nanometers in diameter, can be precisely designed by varying the surfactant type, concentration, and temperature during synthesis. This parameter enables the creation of monodispersed, spherical particles with specific pore structures. The size and morphology of both the particles and their holes can be adjusted to accept a wide range of therapeutic substances, from tiny molecules to big proteins and nucleic acids. [10]

MSNs have a variety of customizable physicochemical features, such as particle and pore size, surface area, and surface chemistry. Their porosity networks allow them to host and release a diverse range of biomolecules, making them extremely adaptable as drug delivery vehicles. The pore diameter, which can be varied between 2 and 50 nanometers, dictates the size of molecules that can be loaded, whilst the large surface area allows for significant drug loading, often exceeding 35% by weight. MSNs can have a variety of pore geometries, including hexagonal, cubic, and worm-like, and their surfaces can be functionalized with different chemical groups to improve host-guest interactions and drug release patterns. [11]

Despite substantial research, MSNs have yet to acquire FDA approval for medicinal usage, owing to the necessity for thorough investigations on their biodistribution, clearance, and long-term destiny in the body. Biokinetics, which includes adsorption, distribution, metabolism, and elimination, determines their performance. MSNs are usually given as intravenous, subcutaneous, or intratumoral injections, and their stability in physiological fluids is critical for optimal drug administration. The silica matrix of MSNs gradually dissolves in the body, converting to orthosilicic acid, a biocompatible substance eliminated in urine. The degradation rate can be adjusted by changing particle properties or integrating different additives, allowing for regulated release kinetics tailored to specific applications. [12]

Biodistribution studies in animal models have demonstrated that MSNs aggregate in reticuloendothelial system organs such as the liver, spleen, and lungs, with particle size, surface functionalisation, and shape all influencing this. Surface changes, such as PEGylation, can lengthen circulation time and affect biodistribution, whereas cationic or elongated particles may aggregate more quickly in specific organs. Ultimately, most MSNs are eliminated from the body through renal excretion. Continued research into the safety, degradation, and biodistribution of MSNs is critical for their future clinical application as effective and safe drug delivery nanocarriers. [13]

Figure 3. Representative roadmap for a MSNs platform to reach the preclinical studies, including the synthesis of the MSNs, demonstration of their stability, therapeutic cargo loading into the pores, Quality Assurance or characterization the loaded platform, smart release behavior, penetration into tumor mass, cellular uptake and in vivo evaluation. [10]

Protein based Nanoparticles

Protein nanoparticles are highly desired due to their low toxicity, biodegradability, and biocompatibility. Their small size enables effective transport across biological barriers and targeted delivery of specific cells or tissues, frequently via endocytosis. These nanoparticles provide various advantages over synthetic carriers, including ease of surface modification, precise control over particle size, and lower immunogenicity. Furthermore, they can shield encapsulated medicines against enzymatic degradation and quick renal clearance, improving drug stability, activity, and half-life. Protein nanoparticles are being investigated for a wide range of therapeutic applications, including as lung delivery, cancer therapy, tumour targeting, and vaccine delivery, mostly due to their non-antigenic nature and versatility. [14]

Protein nanoparticles are designed and prepared using a variety of approaches, including chemical (emulsion and complex coacervation), physical (electrospray and nano spray drying), and self-assembly processes such as desolvation. Each approach has unique advantages and disadvantages in terms of scalability, encapsulation efficiency, and particle control. The primary goal of nanoparticle design is to optimise particle size, surface area, and surface characteristics to achieve the desired pharmacological activity and site-specific drug release. [14,15]

Silk fibroin, the principal protein found in silk fibres, highlights the potential for protein-based nanoparticles in medication delivery. Fibroin, derived from Bombyx mori silkworms, has a semi-crystalline structure with both hydrophobic and hydrophilic domains, which contributes to mechanical strength, stability, and flexibility. Fibroin nanoparticles can be created using procedures such as desolvation, which generally involves the use of surfactants and stabilisers. The resultant particles have good biocompatibility, low immunogenicity, and variable surface charges, which can be adjusted using crosslinking agents like polyethyleneimine (PEI) or EDC to optimise drug encapsulation and release profiles. [16]

Table 1. Advantages and disadvantages of each protein nanoparticles. [14]

Material	Advantage	Disadvantage
Silk protein fibroin	High stability Flexibility with high mechanical strength, suitable for various machining conditions Low immunogenicity Biodegradability Biocompatibility	Sericin may cause immunogenic reactions Slow degradation of silk II crystalline antiparallel B-sheet domains
Human serum albumin	High stability High solubility in physiological fluids Biodegradability Non-immunogenicity Non-toxic Availability and readiness	Expensive cost
Gliadin	Biocompatibility Biodegradability Non-Immunogenicity Non-toxic High stability	Large particle size Rapid degradation speed
Gelatin	Biocompatibility Biodegradability Ease of bridge Safety	Low mechanical strength Rapid degradation speed
Legumin	Bioadhesive Wide surface area small particle size Low immunogenicity High stability	Low yield
30Kc19	High stability Increased cell growth and viability Biodegradability Non-immunogenicity Non-toxic Enzyme-stabilizing property Cell-penetrating property	Low nanoparticle size and yield when using only 30Kc19x
Lipoprotein	Non-immunogenicity Biodegradability Biocompatibility Long circulation half-life Naturally targeting property	Difficult to separate native LDL
Ferritin	High stability pH stability Thermal stability Biodegradability	High cost

Fibroin nanoparticle features, such as size, surface charge, and crystallinity, are regulated by fibroin molecular weight, solvent choice, salt concentration, and processing conditions. These characteristics influence the drug loading capacity, release kinetics, and physical stability of nanoparticles. Fibroin nanoparticles, for example, have been shown to encapsulate a variety of therapeutic agents, including small molecules, natural compounds (e.g., quercetin, resveratrol), and enzymes, resulting in improved drug solubility, sustained release, increased therapeutic efficacy, and decreased toxicity. The synergistic effects discovered when combining fibroin with specific medications emphasise the potential of protein-based nanoparticles in enhancing drug delivery technology. [17,18]

In conclusion, protein-based nanoparticles are a viable platform for nanoparticle-based drug delivery due to their intrinsic biocompatibility, diversity in drug encapsulation, and ability to improve the therapeutic profile of a variety of medications. Ongoing research continues to enhance preparation processes and broaden the repertory of proteins employed, seeking to maximise clinical advantages while minimising potential negatives. [16,17,18]

Polymeric Nanoparticles

Polymeric nanoparticles are nanoscale carriers made from natural or synthetic polymers and typically range in size from 1 to 1000 nanometres. Their fundamental attractiveness in drug delivery arises from their capacity to carefully adjust size, shape, surface charge, and functionalisation, which allows for tailored interactions with biological systems and targeted distribution to specific tissues or cells. Common polymers utilised include polyethylene glycol (PEG), polylactide-co-glycolide (PLGA), and chitosan, among others.

These nanoparticles can encapsulate a wide range of therapeutic agents, such as small molecule medicines, proteins, genes, and imaging agents, improving medication solubility, stability, and bioavailability—particularly for hydrophobic pharmaceuticals that are difficult to administer. Encapsulation also protects medications against enzymatic breakdown and early clearance, resulting in more effective transport to the desired location of action. Polymeric nanoparticles can be created for regulated and prolonged drug release, which reduces dosing frequency and minimises systemic negative effects. [19]

Surface modification of polymeric nanoparticles with targeting ligands enables site-specific distribution, which is very useful in treating cancer, central nervous system illnesses, and infectious infections. Their biocompatibility and low immunogenicity make them ideal for repeated administration without causing substantial side effects. Furthermore, polymeric nanoparticles have found applications in vaccine distribution, where they boost antigen stability and immunogenicity, and in biosensing, where they can be functionalised to high specificity and sensitivity. [20]

Characterising polymeric nanoparticles is critical for their development and application. Electron microscopy (SEM, TEM), dynamic light scattering (DLS), and atomic force microscopy (AFM) are used to examine the morphology, size, and surface properties. Important factors include zeta potential, which effects colloidal stability and interactions with biological membranes, as well as porosity, which affects drug loading capacity and release kinetics. Many polymeric nanoparticles’ dynamic, reversible self-assembly enables them to remain stable during circulation until disassembling at the target region to release their therapeutic cargo. [21]

Despite its numerous benefits, polymeric nanoparticles’ clinical translation is restricted due to constraints such as large-scale manufacture, repeatability, and regulatory hurdles. Current research focusses on optimising their design, understanding their interactions with biological systems, and addressing safety and efficacy problems to fully realise their potential in modern medicine. [20, 21]

Magnetic Nanoparticles

Magnetic nanoparticles (MNPs) have gained popularity in biomedical applications, particularly drug delivery, due to their unique capacity to be modulated by external magnetic fields. Originally utilised as contrast agents in MRI and for cell sorting, their use has grown to encompass targeted medication and gene delivery, as well as magnetic hyperthermia for cancer treatment.

Figure 4. Schematic representation of a magnetic nanoparticle-based drug delivery system. [22]

Magnetic nanoparticle-based drug delivery’s key advantage is its ability to target specific sites. Therapeutic drugs can be attached to MNPs and directed to a target (such as a tumour) using an external magnetic field to localise drug accumulation, limiting systemic dispersion and minimising negative effects associated with chemotherapy. Once concentrated at the target region, the therapeutic substance is released, which is frequently triggered by physiological changes such as pH, temperature, or enzymatic activity, resulting in increased drug uptake by sick cells.

Magnetic targeting works on the basis that magnetic nanoparticles suffer translational force in a magnetic field gradient, allowing them to be confined and concentrated at specified locations. The magnetic characteristics and size of the nanoparticles, the strength and shape of the applied magnetic field, and physiological considerations such as blood flow and tissue depth all have a significant impact on the success of this method. Effective targeting is easier to achieve for surface tissues and regions with slower blood flow, but deeper targets and fast circulation pose considerable hurdles for magnetic capture. [22]

MNPs are typically synthesised with a core-shell structure, where the core consists of magnetic iron oxides like magnetite (Fe₃O₄) or maghemite (γ-Fe₂O₃), and the shell is made from polymers (e.g., silica, dextran, PVA) or metals (e.g., gold), which can be further functionalised with targeting ligands, antibodies, or drugs. Other ways involve embedding MNPs in hydrogels or creating magnetoliposomes, which increase their adaptability for drug delivery and hyperthermia applications. Recent improvements have resulted in the development of gold/cobalt core-shell nanoparticles with greater magnetic moments, which provide increased magnetic responsiveness.

Despite promising results in animal research, the introduction of magnetic nanoparticle-based drug delivery into clinical practice confronts various challenges. These include issues in producing adequate magnetic field strength and gradient at deep tissue sites, the risk of embolisation, off-target accumulation (particularly in the liver), and scaling up from small animal models to humans. Early clinical trials have had limited but positive results, particularly for targeting liver tumours, where MR imaging and angiography were employed to optimise administration. [23]

Beyond medication delivery, MNPs are being investigated for magnetic hyperthermia, in which localised heating caused by alternating magnetic fields induces tumour cell apoptosis, and for gene delivery, in which MNPs transport therapeutic genes directly to target cells.

Magnetic nanoparticles are a highly promising platform for targeted medication and gene delivery, with the potential to transform cancer therapy and other therapies by increasing efficacy and lowering side effects. Continued research is aimed at overcoming present constraints, optimising nanoparticle design, and advancing clinical translation in order to fully realise their therapeutic promise. [22, 23]

Smart Nanoparticles

Smart nanoparticles are a cutting-edge breakthrough in nanoparticle-based medication delivery that addresses many of the limitations associated with standard drug formulations and previous nanoparticle systems. Unlike traditional tablets or granules, which provide limited control over medication release and distribution, smart nanoparticles can be made to respond to specific physiological triggers—such as pH, temperature, or enzyme activity—allowing for precise, on-demand drug release at the target site. [24]

Nanoparticles have a distinct attraction in drug delivery due to their enormous surface area, which allows for improved drug loading and interaction with biological surroundings. While nanoparticles are commonly defined as having dimensions between 1 and 100 nm, the most essential distinction is their ability to display unique features not found in bulk materials. These advantages include better solubility for poorly water-soluble pharmaceuticals, increased circulation time by surface modifications (such as PEGylation), and the ability to transport many medications in a single carrier. [24,25]

Smart nanoparticles can be designed for passive or active targeting. Passive targeting frequently takes advantage of the increased permeation and retention (EPR) effect, in which nanoparticles concentrate more readily in tumour tissue due to leaky vasculature. However, while this effect has been established in animal models, it typically results in only a minor increase in medication concentration at the tumour site—usually just 2-5% of the injected dose—highlighting the need for additional improvements. Active targeting entails surface functionalisation with ligands or antibodies that bind precisely to target cells, enhancing cellular absorption. However, converting these advantages from cell culture and animal models to therapeutic success in humans is still a considerable issue. [25]

Smart nanoparticles have been utilised in pharmaceutical applications to improve medication bioavailability, particularly for those with low water solubility, by improving the dissolution rate and concentration gradient for absorption. Drug nanocrystal technologies have resulted in some clinically useful formulations; however, their development and stabilisation necessitate advanced technical solutions.

Despite its promise, the field must overcome a number of misconceptions and constraints. Many nanoparticle-based systems were established through trial and error rather than logical design, and the actual clinical effects, particularly for targeted cancer therapy, are frequently less dramatic than expected. To realise their full potential, smart nanoparticles require a better knowledge of their in vivo behaviour as well as more rigorous testing of their efficacy and safety. [26]

In summary, smart nanoparticles have considerable benefits for drug administration, including as tailored release, increased solubility, and the ability to elude immune clearance. However, achieving their full therapeutic potential would necessitate overcoming current technological and biological barriers through ongoing research and innovation. [24,25,26]

Nanoparticle Based Drug Delivery in Cancer

Therapeutic nanoparticles have emerged as a promising option for addressing several long-standing issues in cancer medication delivery, including nonspecific dispersion, poor water solubility of many chemotherapeutic drugs, low oral bioavailability, and restricted therapeutic indices. Researchers have been able to extend nanoparticles’ circulation period in the bloodstream and improve their selective aggregation in tumour tissues by carefully altering their size and surface qualities. This selectivity is achieved through both passive targeting mechanisms, such as the enhanced permeability and retention (EPR) effect, which takes advantage of tumours’ leaky vasculature, and active targeting strategies, which involve functionalising the nanoparticle surface with ligands or antibodies that specifically recognise and bind to tumor-associated markers. [27,28]

One of the most notable advantages of nanoparticle-mediated drug delivery in cancer therapy is its capacity to overcome multidrug resistance, which is a major impediment to effective treatment. Nanoparticles can penetrate cancer cells by endocytosis and bypass efflux pumps such as P-glycoprotein, enhancing chemotherapy drugs’ intracellular concentration and potency. The creation of multifunctional nanoparticles, which can co-deliver numerous medications or combine therapeutic and diagnostic activities, is a promising frontier in personalised cancer treatment. [28,29]

Polymeric nanoparticles made from both natural and synthetic polymers, polymeric micelles with hydrophobic cores and hydrophilic shells, dendrimers with highly branched and modifiable surfaces, liposomes composed of lipid bilayers, viral nanoparticles engineered for tumour targeting, and carbon nanotubes modified for biocompatibility have all been investigated for cancer drug delivery purposes. These systems can encapsulate, entrap, or conjugate medicines, preventing them from degrading and allowing for regulated and prolonged release at the tumour site. Nanoparticles are normally designed to be fewer than 100 nanometres in diameter and to have hydrophilic surfaces, which are often obtained through PEGylation, allowing them to elude immune system clearance and prolong their circulation time. [27,29]

Despite these gains, significant hurdles remain, including improving oral bioavailability, bloodstream stability, and tissue-specific distribution while minimising possible toxicity. Nonetheless, therapeutic nanoparticles have been shown to boost drug concentrations at tumour locations, lower off-target toxicity, and improve overall patient outcomes. Ongoing research focusses on improving nanoparticle design and developing multifunctional and targeted delivery methods in order to improve the efficacy and safety of cancer treatments. [30]

Safety and Hazards

Nanoparticle-based drug delivery systems have dramatically expanded the possibilities for therapeutic intervention in a wide range of medical fields, thanks to their unique ability to improve drug release kinetics, stability, and site-specific targeting while minimising systemic toxicity and side effects. In oncology, these systems have transformed chemotherapy administration by allowing targeted accumulation in tumour tissues via both passive mechanisms, such as the increased permeability and retention (EPR) effect, and active targeting tactics employing surface ligands and antibodies. This tailored strategy not only enhances drug concentration at the tumour location, but it also aids in the treatment of multidrug resistance and minimises collateral damage to healthy tissues. Beyond cancer, nanoparticle-based systems are being used to treat cardiovascular diseases, neurodegenerative disorders, infectious diseases, and chronic inflammatory conditions, as well as gene therapy, where they aid in the delivery of nucleic acids and gene-editing components to targeted cells. [31]

Nanoparticles are used in diagnostics as imaging agents to improve illness detection sensitivity and specificity, as well as platforms for biosensing and biomarker identification. Recent breakthroughs have also combined nanoparticles with personalised medicine approaches, enabling for the creation of highly customised therapy regimens that take into account individual patient variation. Nanoparticle design may be fine-tuned to enable controlled and stimuli-responsive medication release, which improves therapeutic precision. Innovations like as ligand attachment, PEGylation, and the insertion of smart, stimuli-responsive components have greatly increased medication bioavailability, regulated release profiles, and reduced adverse effects.

The safety of nanoparticle-based drug delivery systems is generally favourable when biocompatible and biodegradable materials, such as lipids, polymers, or proteins, are used, which are tailored to avoid immune detection and allow for safe removal from the body. Encapsulation protects medications from early breakdown and lowers the risk of local irritation, while surface changes can further reduce immunogenicity. However, there are still potential risks, such as unintended accumulation in organs such as the liver and spleen, long-term persistence of non-biodegradable materials, and the possibility of unexpected toxicities or immune responses as a result of interactions with biological barriers and cellular components. The intricacy of nanoparticle compositions presents obstacles for large-scale manufacturing, regulatory approval, and quality control, necessitating comprehensive preclinical and clinical testing. [32]

Emerging advances in the field include the use of microrobotics for precise drug administration, enhanced materials engineering for more effective and sustainable nanoparticles, and the integration of nanotechnology with digital health and smart devices for real-time monitoring and adaptive therapy. Manufacturing advancements, such as microfluidic mixing and green synthesis technologies, enable nanoparticle manufacturing to be scaled up while maintaining quality and reproducibility. As research continues to address the remaining safety, efficacy, and regulatory challenges, nanoparticle-based drug delivery systems are poised to play a critical role in the next generation of precision medicine, providing safer, more effective, and patient-friendly therapeutic options for a wide range of diseases. [33]

CONCLUSION

In conclusion, the rapid growth of nanotechnology has radically altered the landscape of drug delivery, providing new opportunity to overcome the constraints of traditional treatment techniques. Nanoparticles, with their variable size, huge surface area, and flexible surface modification capabilities, have emerged as highly effective carriers for targeted and regulated drug delivery. The variety of nanoparticle systems, including polymeric, protein-based, magnetic, and mesoporous silica nanoparticles, has allowed for the development of platforms customised to various therapeutic objectives, ranging from increased drug solubility and stability to precise site-specific delivery. These improvements have had a particularly large impact in oncology, where targeted delivery not only improves therapeutic efficacy but also significantly reduces systemic toxicity.

The development of smart nanoparticles and externally guided systems, such as magnetic nanoparticles, emphasises the amazing adaptability of these nanocarriers. By responding to physiological inputs or external fields, these sophisticated devices can accomplish on-demand medication delivery and enhanced disease site accumulation. This level of control paves the path for personalised medicine, in which treatment regimens are matched to unique patient profiles, maximising therapeutic effectiveness while minimising side effects. Furthermore, the use of nanoparticles in diagnostics and imaging improves illness detection sensitivity and specificity, enabling earlier and more accurate therapies.

Despite these tremendous accomplishments, the transition of nanoparticle-based drug delivery systems from the laboratory to clinical practice presents various hurdles. Large-scale manufacturing, reproducibility, long-term safety, and regulatory compliance continue to be significant challenges. The complexities of nanoparticle interactions with biological systems demand comprehensive preclinical and clinical testing to ensure efficacy and safety. Concerns about potential toxicity, unexpected biodistribution, and the persistence of non-biodegradable elements in the body highlight the need for continued research focused on optimising nanoparticle design and surface properties.

The safety and hazard profiles of these systems are directly related to their physicochemical features, such as size, shape, surface chemistry, and composition. While many nanoparticle formulations use biocompatible and biodegradable materials to reduce immune reactions and promote safe clearance, it is important to consider the possibility of off-target effects and accumulation in organs such as the liver and spleen. Regulatory bodies and researchers must continue to prioritise rigorous toxicological evaluations and the creation of standardised methodologies for assessing the safety of new nanomedicines.

Looking ahead, the future of nanoparticle-based medicine delivery looks quite promising. Continued interdisciplinary collaboration, technological innovation, and regulatory harmonisation are required to fully realise the potential of these systems. As our understanding of nanoparticle-biology interactions grows and manufacturing methods progress, nanoparticle-based drug delivery has the potential to transform not only cancer therapy but also the treatment of a wide range of disorders. Finally, these developments hold the potential of safer, more effective, and patient-centered therapy alternatives, ushering in a new era of precision medicine and increasing the quality of life for patients worldwide.

REFERENCES

1. Afzal, O., Altamimi, A. S. A., Nadeem, M. S., Alzarea, S. I., Almalki, W. H., Tariq, A., Mubeen, B., Murtaza, B. N., Iftikhar, S., Riaz, N., & Kazmi, I. (2022). Nanoparticles in Drug Delivery: From History to Therapeutic Applications. Nanomaterials, 12(24), 4494.
2. Li, S.; Zhang, H.; Chen, K.; Jin, M.; Vu, S.H.; Jung, S.; He, N.; Zheng, Z.; Lee, M.S. Applicatio of chitosan/alginate nanoparticle in oral drug delivery systems: Prospects and challenges. Drug Deliv. 2022, 29, 1142–1149.
3. Vlachopoulos, A.; Karlioti, G.; Balla, E.; Daniilidis, V.; Kalamas, T.; Stefanidou, M.; Bikiaris, N.D.; Christodoulou, E.; Koumentakou, I.; Karavas, E.; et al. Poly (Lactic Acid)-Based Microparticles for Drug Delivery Applications: An Overview of Recent Advances. Pharmaceutics 2022, 14, 359.
4. Alshammari, M.K.; Alshehri, M.M.; Alshehri, A.M.; Alshlali, O.M.; Mahzari, A.M.; Almalki, H.H.; Kulaybi, O.Y.; Alghazwni, M.K.; Kamal, M.; Imran, M. Camptothecin loaded nano-delivery systems in the cancer therapeutic domains: A critical examination of the literature. J. Drug Deliv. Sci. Technol. 2022, 79, 104034.
5. Marco-Dufort, B.;Willi, J.; Vielba-Gomez, F.; Gatti, F.; Tibbitt, M.W. Environment Controls Biomolecule Release from Dynamic Covalent Hydrogels. Biomacromolecules 2021, 22, 146–157.
6. Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H. (2012). Nanoparticles as drug delivery systems. Pharmacological reports, 64(5), 1020-1037.
7. Abdel-Mottaleb MMA, Neumann D, Lamprecht A: Lipid nanocapsules for dermal application: A comparative study of lipid-based versus polymer-based nanocarriers. Eur J Pharm Biopharm, 2011, 79, 36–42.
8. Ai J, Biazar E, Montazeri M, Majdi A, Aminifard S, Safari M, Akbari HR: Nanotoxicology and nanoparticle safety in biomedical designs. Int J Nanomedicine, 2011, 6, 1117–1127.
9. Beg S, Rizwan M, Sheikh AM, Hasnain MS, Anwer K, Kohli K: Advancement in carbon nanotubes: basics, biomedical applications and toxicity. J Pharm Pharmacol, 2011, 63, 141–163.
10. Manzano, M. Vallet-Regí, Mesoporous Silica Nanoparticles for Drug Delivery. Adv. Funct. Mater.2020, 30, 1902634.
11. Vallet-Regí, Bioceramics: from bone substitutes to nanoparticles for drug delivery. Pure Appl. Chem. 2019, 91, 687.
12. Mora-Raimundo, D. Lozano, M. Manzano, M. Vallet-Regí, ACS Nano 2019, 13, 5451.
13. R. Castillo, D. Lozano, B. González, M. Manzano, I. Izquierdo-Barba, M. Vallet- Regí, Expert Opin. Drug Deliv. 2019, 16, 415.
14. Hong, S., Choi, D. W., Kim, H. N., Park, C. G., Lee, W., & Park, H. H. (2020). Protein-Based Nanoparticles as Drug Delivery Systems. Pharmaceutics, 12(7), 604.
15. Yang, S.-A.; Choi, S.; Jeon, S.M.; Yu, J. Silica nanoparticle stability in biological media revisited. Sci. Rep. 2018, 8, 185.
16. Carvalho, M.R.; Carvalho, C.R.; Maia, F.R.; Caballero, D.; Kundu, S.C.; Reis, R.L.; Oliveira, J.M. Peptide-Modified Dendrimer Nanoparticles for Targeted Therapy of Colorectal Cancer. Adv. Ther. 2019, 2, 1900132.
17. Song, W.; Gregory, D.A.; Al-janabi, H.; Muthana, M.; Cai, Z.; Zhao, X. Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer cells. Int. J. Pharm. 2019, 555, 322–336.
18. Jacob, J.; Haponiuk, J.T.; Thomas, S.; Gopi, S. Biopolymer based nanomaterials in drug delivery systems: A review. Mater. Today Chem. 2018, 9, 43–55.
19. Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024). Polymeric nanoparticles for drug delivery. Chemical Reviews, 124(9), 5505-5616.
20. Zhang, Y.; Sun, C.; Wang, C.; Jankovic, K. E.; Dong, Y. Lipids and lipid derivatives for RNA delivery. Chem. Rev. 2021, 121, 12181− 12277.
21. Vargason, A. M.; Anselmo, A. C.; Mitragotri, S. The evolution of commercial drug delivery technologies. Nat. Biomed. Eng 2021, 5, 951−967.
22. Dobson, J. (2006). Magnetic nanoparticles for drug delivery. Drug development research, 67(1), 55-60.
23. Assa, F., Jafarizadeh-Malmiri, H., Ajamein, H., Vaghari, H., Anarjan, N., Ahmadi, O., & Berenjian, A. (2017). Chitosan magnetic nanoparticles for drug delivery systems. Critical reviews in biotechnology, 37(4), 492-509.
24. Lee, B. K., Yun, Y. H., & Park, K. (2015). Smart nanoparticles for drug delivery: Boundaries and opportunities. Chemical engineering science, 125, 158-164.
25. Thoma CR, Zimmermann M, Agarkova I, Kelm JM, Krek W. 3D cell culture systems modeling tumor growth determinants in cancer target discovery. Advanced Drug Delivery Reviews. 2014; 69–70:29–41.
26. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Advanced Drug Delivery Reviews. 2012; 64(Supplement):206–212.
27. Kwangjae Cho, Xu Wang, Shuming Nie, Zhuo (Georgia) Chen, Dong M. Shin; Therapeutic Nanoparticles for Drug Delivery in Cancer. Clin Cancer Res 1 March 2008; 14 (5): 1310–1316.
28. Bahrami, B., Hojjat-Farsangi, M., Mohammadi, H., Anvari, E., Ghalamfarsa, G., Yousefi, M., & Jadidi-Niaragh, F. (2017). Nanoparticles and targeted drug delivery in cancer therapy. Immunology letters, 190, 64-83.
29. Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., … & Shao, A. (2020). Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Frontiers in molecular biosciences, 7, 193.
30. Dang, Y., & Guan, J. (2020). Nanoparticle-based drug delivery systems for cancer therapy. Smart materials in medicine, 1, 10-19.
31. De Jong, W. H., & Borm, P. J. (2008). Drug delivery and nanoparticles: Applications and hazards. International Journal of Nanomedicine, 3(2), 133–149.
32. Leite, P. E. C., Pereira, M. R., & Granjeiro, J. M. (2015). Hazard effects of nanoparticles in central nervous system: searching for biocompatible nanomaterials for drug delivery. Toxicology in vitro, 29(7), 1653-1660.
33. Sharma, S., Parveen, R., & Chatterji, B. P. (2021). Toxicology of nanoparticles in drug delivery. Current pathobiology reports, 1-12.